Invention Grant
- Patent Title: Anti-TNF-α/CXCL10 double-targeting antibody and use thereof
-
Application No.: US14893071Application Date: 2014-05-22
-
Publication No.: US10087248B2Publication Date: 2018-10-02
- Inventor: Heun-Soo Kang , So-Hyun Park , Yeong Wook Song , Ki Chul Shin , Eun Young Lee , Eun Bong Lee , Young Woo Park , Bum-Chan Park , Dong Hee Lee , Dong Jin Kim , Seon Ha Yun , Ke Se Lee , Hyun Ju Lee , Kyung Jin Kim , Hee Chan Kim , Seok Ho Yoo , Myeoung Hee Jang , Seil Jang
- Applicant: METABOLIC ENGINEERING LABORATORIES CO., LTD.
- Applicant Address: KR Seoul
- Assignee: METABOLIC ENGINEERING LABORATORIES CO., LTD.
- Current Assignee: METABOLIC ENGINEERING LABORATORIES CO., LTD.
- Current Assignee Address: KR Seoul
- Agency: Hamilton DeSanctis & Cha, LLP
- Agent Don D. Cha
- Priority: KR10-2013-0057475 20130522; KR10-2013-0057762 20130522
- International Application: PCT/KR2014/004579 WO 20140522
- International Announcement: WO2014/189306 WO 20141127
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/24 ; C12N5/10 ; C07K16/46 ; A61K39/00

Abstract:
The present invention relates to a TNF-α (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-α specific antibody, is a bispecific antibody that effectively binds to both TNF-α and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-α/CXCL10. A composition of the present invention comprises a TNF-α/CXCL-10 double targeting antibody which effectively binds to both TNF-α and CXCL10. The double targeting antibody of the present invention has excellent TNF-α inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-α or CXCL10 single targeting antibody. The composition of the present invention can be used in preventing or treating immunological disease.
Public/Granted literature
- US20160108118A1 Anti-TNF-alpha/CXCL10 Double-Targeting Antibody and Use Thereof Public/Granted day:2016-04-21
Information query